Spots Global Cancer Trial Database for castration resistant
Every month we try and update this database with for castration resistant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer | NCT01000948 | Prostate Cancer Metastasis | ZD4054 | 18 Years - 90 Years | Aarhus University Hospital | |
| Abiraterone Acetate for Castrate Resistant Prostate Cancer | NCT01961843 | Prostate Cancer | Abiraterone Prednisone | 18 Years - | Massachusetts General Hospital | |
| Open Label Prostate Cancer Study | NCT01162395 | Prostate Cancer | AZD3514 | 20 Years - 130 Years | AstraZeneca | |
| A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | NCT04087174 | Prostate Cancer | Capivasertib Enzalutamide Abiraterone | 18 Years - 130 Years | AstraZeneca | |
| OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470 | Castration Resi... | OGX-427 Prednisone | 18 Years - | British Columbia Cancer Agency | |
| XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937 | Prostate Cancer | Cabozantinib Abiraterone | 18 Years - | Dana-Farber Cancer Institute | |
| Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 | NCT02981797 | Prostate Cancer Prostate Adenoc... | Blood Collectio... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | NCT02903160 | Prostate Cancer | Abiraterone ace... Prednisone Radium-223 dich... cabazitaxel Carboplatin Enzalutamide | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937 | Prostate Cancer | Cabozantinib Abiraterone | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05348577 | Prostate Cancer | capivasertib docetaxel placebo docetaxel | 18 Years - 130 Years | AstraZeneca | |
| A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | NCT04087174 | Prostate Cancer | Capivasertib Enzalutamide Abiraterone | 18 Years - 130 Years | AstraZeneca | |
| Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer | NCT01804465 | Prostate Cancer | SipT Treatment Ipilimumab | 18 Years - | University of California, San Francisco | |
| Abiraterone Acetate Trial in African American Prostate Cancer Patients | NCT01735396 | Prostate Cancer | Abiraterone Ace... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Abiraterone Acetate Trial in African American Prostate Cancer Patients | NCT01735396 | Prostate Cancer | Abiraterone Ace... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Abiraterone Acetate for Castrate Resistant Prostate Cancer | NCT01961843 | Prostate Cancer | Abiraterone Prednisone | 18 Years - | Massachusetts General Hospital | |
| Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca | NCT01289067 | Prostate Cancer | Satraplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer | NCT01541007 | Metastatic Cast... | Cabazitaxel weekly cabazita... | 18 Years - | Karolinska University Hospital | |
| OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470 | Castration Resi... | OGX-427 Prednisone | 18 Years - | British Columbia Cancer Agency | |
| Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | NCT01347788 | Prostate Adenoc... | cabozantinib | 18 Years - | Massachusetts General Hospital | |
| Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer | NCT02415621 | Prostate Cancer | Abiraterone Ace... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470 | Castration Resi... | OGX-427 Prednisone | 18 Years - | British Columbia Cancer Agency | |
| Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca | NCT01289067 | Prostate Cancer | Satraplatin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| An Open Label Prostate Cancer Study in Japanese Patients | NCT01351688 | Prostate Cancer | AZD3514 | 20 Years - | AstraZeneca | |
| Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer | NCT01478308 | Prostate Cancer | Metformin hydro... Docetaxel Prednisone | 18 Years - | New Mexico Cancer Care Alliance | |
| Open Label Prostate Cancer Study | NCT01162395 | Prostate Cancer | AZD3514 | 20 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
